SEARCH:   Advanced

Blood, Vol. 109, Issue 3, 951-953, February 1, 2007 This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy Blood Weng et al. 109: 951 Supplemental materials for: Weng et al, Vol 109, Issue 3, 951-953 Files in this Data Supplement: Table S1. Patient characteristics according to chemotherapy response (PDF, 19.9 KB) Table S2. Induction chemotherapy and response (PDF, 10.9 KB) Table S3. Follicular lymphoma international prognostic index (PDF, 10.9 KB) Figure S1. Kaplan-Meier estimates of progression-free survival by FLIPI risk groups, and humoral immune response and V/V genotype (JPG, 37.6 KB) - Progression-free survival curves were plotted by FLIPI risk groups (A), or by humoral anti-Id immune responses and/or FcRIIIa 158 V/V genotype in FLIPI low-risk (B) and intermediate/high-risk (C) patients. CR represents patients with complete response or unconfirmed complete response. PR represents patients with partial response. Other represents patients without either anti-Id antibodies or FcRIIIa 158 V/V genotype. TTP indicates median time to progression. This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020